Cardiology

Etripamil 70 mg nasal spray restored heart rate within 30 minutes in approximately 60% of PSVT episodes, report authors of new study.

The 2022 AAFP Clinical Practice Guideline on hypertension treatment in adults is the subject matter for this 10-question topline quiz that is also a good source of review.

Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.

The biosimilar to the GLP-1 mimetic Victoza proved noninferior for reduction of HbA1c and had similar positive effects on body weight, lipids, and blood pressure.

Empagliflozin is approved to lower the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with CKD at risk of progression.

Your daily dose of the clinical news you may have missed.

Waist-to-hip ratio was more powerfully and consistently associated with risk of all-cause mortality than BMI or FMI, but can it replace BMI as a clinical indicator?

The USPSTF recommends that BP be checked at all prenatal visits for all pregnant persons and calls for reducing vast inequities in maternal health care.

Your daily dose of the clinical news you may have missed.

The AZALEA-TIMI 71 trial was stopped early due to an "overwhelming reduction" in a composite endpoint of major bleeding events compared to rivaroxaban standard of care.

Results from a new study show that older adults with untreated hypertension had a 42% increased risk of dementia vs healthy controls.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of clinical news you may have missed.

This guideline topline summary of recommendations for treating hypertension in adults is adapted from the American Academy of Family Physicians clinical guideline.

The selective aldosterone synthase inhibitor will move into late stage clinical trials, a nod to the potential for a first-in-class agent targeting aldosterone.

The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?

Women with an evening vs morning chronotype were 54% more likely to have unhealthy lifestyles that in turn accounted for a significant increased risk for diabetes.

New research presented at Hypertension 2023 showed a novel digital bilingual hypertension control program improved BP control rates by more than 30%.

Your daily dose of clinical news you may have missed.

Persons with HTN while in a supine position had a higher risk for CVD even if they did not have HTN while seated, according to new research presented at Hypertension 2023.

Your daily dose of clinical news you may have missed.

Get a quick look at the US worst states for health care ranked using a composite score that included measures of cost, access, and outcomes.

New research shows that patients with heart failure who had more steps per day and increasing steps per day experienced better health status over 12 weeks.

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

ESC 2023: New data showed an aspirin-free strategy after PCI did not reduce major bleeding event risk vs DAPT, while omission of aspirin proved noninferior for CV events in high-risk patients.

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.

ESC 2023: Early initiation of dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in patients hospitalized with ADHF.

A daily dose of clinical news on Patient Care you may have missed.